Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

NCT04857606 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

DRUG: AMG 609
DRUG: Placebo

Sponsor

Amgen